Stryker raises dividend to $0.84 per share

PORTAGE, Michigan - Medical (TASE:PMCN) technology firm Stryker Corporation (NYSE:SYK), with a market capitalization of $149.59 billion, has announced an increase in its quarterly dividend. Today, the company’s Board of Directors declared a dividend of $0.84 per share, which is scheduled to be paid on April 30, 2025, to shareholders who are on record as of March 31, 2025. This represents a 5.0% increase from the previous year and is consistent with the dividend amount from the prior quarter. According to InvestingPro data, Stryker has maintained dividend payments for 34 consecutive years, with 15 straight years of dividend raises.

The dividend increase reflects Stryker’s financial health and its commitment to returning value to its shareholders. With a current dividend yield of 0.86% and impressive revenue growth of 10.23% over the last twelve months, InvestingPro analysis shows the company maintains a GREAT financial health score of 3.15. As a global leader in medical technologies, Stryker is known for its diverse range of products and services across MedSurg, Neurotechnology, and Orthopaedics. These contributions are aimed at enhancing patient and healthcare outcomes. The company has a significant impact on the healthcare industry, touching the lives of over 150 million patients each year.

Investors might view the steady dividend as a sign of Stryker’s stable financial position and its ability to maintain shareholder returns amidst its ongoing efforts to improve healthcare. The declaration of the dividend aligns with the company’s history of providing consistent shareholder value while pursuing growth and innovation within the medical technology sector. For deeper insights into Stryker’s valuation and 13 additional exclusive ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.

This financial news is based on a press release statement from Stryker Corporation.

In other recent news, Stryker has been the subject of several analyst upgrades following its robust Q4 2024 performance. Truist Securities has raised its price target for Stryker to $413, citing factors such as strategic changes within its Spine division and the company’s guidance for 2025. Stifel analysts have increased their price target to $440, following Stryker’s strong Q4 performance and the announcement of strategic business decisions such as the upcoming retirement of its CFO and the sale of its Spine Implant business.

RBC Capital Markets has raised its price target for Stryker to $435 due to the company’s strong Q4 performance and robust initial guide for organic sales, margins, and earnings per share (EPS) growth for 2025. BTIG analyst Ryan Zimmerman increased the price target to $416, following Stryker’s robust and diversified financial results in Q4 2024. Lastly, Bernstein SocGen Group raised its price target from $425.00 to $440.00, noting Stryker’s robust Q4 performance and positive outlook for the future.

These recent developments underline the positive sentiment among analysts about Stryker’s financial health and strategic decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.